主页 文献库文献详情
PMID: 42211497 已发表 · epublish 英语

Predicting survival of patients treated with antibody-drug conjugates in early-phase clinical trials using AI-quantified 3D body composition on CT scans.

Frontiers in oncology ·第 16 卷

Delaye M, Lawrance L, Belkouchi Y, Wirth F, Decazes P, Bône A, Ouali K, Hollebecque A, Smolenschi C, Bahleda R, Gazzah A, Champiat S, Danlos FX, Hénon C, Beshiri K, Sakkal M, Marabelle A, Michot JM, Ribrag V, Parisi C, Massard C, Goldschmidt V, Vera P, Ponce-Aix S, Lassau N, Ammari S, Baldini C

摘要

Body composition has a significant impact on the prognosis of cancer patients. However, little is known about its impact on the efficacy and safety of antibody-drug conjugates (ADCs), despite the need for accurate patient profiling to ensure reliable safety data and early signals of activity. All patients treated with ADCs in early-phase clinical trials between March 2015 and March 2023 in our institution were retrospectively included in the analysis. Pre-treatment injected CT scans were acquired for all patients. A deep learning software, Anthropometer3DNet, automatically quantified anthropometric parameters in three dimensions (3D) on the acquired CT scans: skeletal muscle mass (SMM), total adipose tissue (TAT), subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and lean body mass (LBM). The effect of these anthropometric parameters on progression-free survival (PFS), overall survival (OS), and time in protocol (TIP) was analyzed. A total of 136 patients were included. The median age, Eastern Cooperative Oncology Group Performance Status (ECOG PS), albumin, and number of previous lines of treatment were respectively 60.8 years (30 to 85), 1 (0-2), 42 g/L [interquartile range (IQR): 39-44], and 3 (IQR: 0-2). The median PFS and OS were 2.6 and 7.9 months, respectively; 90 (66%) patients had experienced toxicity (of which 46 were grade 3-5). Univariate analyses showed that higher SAT [hazard ratio (HR) = 0.67, p = 0.03] and TAT (HR = 0.60, p = 0.01) were significantly associated with longer PFS [median PFS (mPFS) = 2.76 vs. 2.3 and 2.76 vs. 1.9, respectively]. Higher SAT (HR = 0.66, p = 0.04) and higher VAT (HR = 0.65, p = 0.04) were significantly associated with longer OS [median OS (mOS) = 9.34 vs. 7.43 months and 9.27 vs. 6.08 months, respectively]. Higher TAT was associated with longer TIP in both univariate and multivariate analyses (HR = 0.56, p = 0.006). A Royal Marsden Hospital (RMH) prognostic score of 2 or more was associated with PFS, OS, and TIP in both univariate and multivariate analyses (HR = 1.78, 1.89, and 1.74, respectively). All anthropometric parameters were significantly associated with all-grade toxicity in the univariate analysis but not in the multivariate analysis. Automatic extraction of body composition parameters using artificial intelligence (AI) may help in anticipating the benefits of ADCs in patients included in early-phase clinical trials. Combining anthropomorphic data with clinical and biological data may lead to more refined patient selection.

关键词
anthropometric parameters antibody-drug conjugates artificial intelligence early-phase clinical trial patient selection
文献信息
期刊
Frontiers in oncology
期刊简称
Front Oncol
ISSN
2234-943X
语言
英语
国家/地区
Switzerland
NLM ID
101568867
分析服务
分析服务

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]